2024
Racial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2021
Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database
Calip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. Blood 2021, 138: 4121. DOI: 10.1182/blood-2021-152774.Peer-Reviewed Original ResearchReal-world progression-free survivalHigh-risk cytogenetic abnormalitiesCurrent equity holderFlatiron HealthBlack patientsWhite patientsMultiple myelomaMM patientsCytogenetic abnormalitiesClinical characteristicsHazard ratioAge groupsAutologous stem cell transplantationAdvisory CommitteeAdult MM patientsCytogenetic risk stratificationOlder black patientsTechnology-enabled abstractionYoung black patientsAdjusted hazard ratioRetrospective cohort studyFirst-line therapyFirst-line treatmentHigh-risk subsetProgression-free survival